# XinThera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xinthera

- Industry: Biotechnology
- Headquarters: San Diego, US
- Total disclosed funding: $50M
- Latest round: Series B (Aug 4, 2021)
- Investors on record: 3

## About

Based in San Diego, US, and founded in 2021, XinThera, LLC. provides precision medicines to treat cancer and immunological diseases. In August 2021, the firm raised USD 50 million in Series B funding from investor OrbiMed Advisors. As of 2022, the company was headed by its CEO Chris LeMasters.

The company offers new opportunities and new therapies that can be used to treat cancer and immunological diseases. The firm designs medicines for the patient by using advanced computational chemistry technologies.

The company plans to use the August 2022 funding to support its recruiting efforts and build its product pipeline.

## Funding rounds

- Series B, Aug 4, 2021, $50M — OrbiMed Advisors, Foresite Capital, TTM Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- TTM Capital (https://capitalatlas.ai/funds/ttm-capital) — Series B